See the DrugPatentWatch profile for Ustekinumab
Ustekinumab, marketed as Stelara, is a monoclonal antibody used to treat conditions like plaque psoriasis, psoriatic arthritis, and Crohn's disease [1]. Patent protection for drugs like ustekinumab is crucial for pharmaceutical companies, allowing them to recoup research and development costs [2].
When does ustekinumab patent exclusivity expire?
The patent landscape for ustekinumab is complex, involving multiple patents covering different aspects of the drug, including its composition of matter and methods of use [3]. Information from DrugPatentWatch.com indicates that key patents for ustekinumab have been or are expected to be challenged and expire in the coming years [4]. For example, the composition of matter patent for ustekinumab has a listed expiration date around 2023, but secondary patents may extend market exclusivity for certain indications [4][5].
What happens if ustekinumab patents are invalidated?
If ustekinumab patents are successfully challenged and invalidated, it can pave the way for generic or biosimilar competition [6]. This typically leads to a significant decrease in drug prices and increased patient access [7]. The process of patent challenges often involves complex legal proceedings, with companies filing Paragraph IV certifications to dispute patent validity [8].
How do ustekinumab biosimilars compare to the original drug?
Biosimilars are highly similar to their reference products, with no clinically meaningful differences in terms of safety, purity, and potency [9]. Once approved, biosimilars can offer a more affordable alternative to ustekinumab, while providing the same therapeutic benefits [10]. The development and approval of biosimilars are regulated by agencies like the FDA to ensure they meet rigorous standards [9].
Who are the main competitors and alternatives to ustekinumab?
Several other biologic drugs compete with ustekinumab in the treatment of inflammatory conditions. For psoriasis and psoriatic arthritis, these include TNF inhibitors (like adalimumab, infliximab), IL-17 inhibitors (like secukinumab, ixekizumab), and IL-23 inhibitors (like risankizumab, guselkumab) [11][12]. For Crohn's disease, alternatives include other TNF inhibitors, vedolizumab, and other IL-12/23 inhibitors [13].
What is the expected timeline for ustekinumab biosimilar market entry?
The entry of biosimilars for ustekinumab is contingent on patent expirations and the outcomes of any patent litigation [4]. While some patents have already expired or are nearing expiration, others may extend exclusivity for specific uses of the drug [4][5]. This means the market entry timeline for biosimilars can vary [4].
What clinical data supports ustekinumab's efficacy?
Clinical trials have demonstrated ustekinumab's effectiveness in achieving and maintaining remission in patients with plaque psoriasis, psoriatic arthritis, and moderate to severe Crohn's disease [1][13]. Studies have shown significant improvements in disease activity scores and quality of life for patients treated with ustekinumab [1][13].
Sources:
[1] https://www.janssen.com/ustekinumab-stelara
[2] https://www.fda.gov/about-fda/pharmaceuticals/drug-innovation-and-competition
[3] https://www.drugpatentwatch.com/ustekinumab
[4] https://www.drugpatentwatch.com/ustekinumab/patents
[5] https://www.drugpatentwatch.com/ustekinumab/exclusivity
[6] https://www.fda.gov/drugs/biosimilars/biosimilar-medical-diagnostics
[7] https://www.fda.gov/drugs/biosimilars
[8] https://www.hklaw.com/en/insights/publications/2022/08/understanding-and-navigating-paragraph-iv-litigation
[9] https://www.fda.gov/drugs/biosimilars/questions-and-answers-regarding-biosimilars
[10] https://www.biosimilar.org/
[11] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887413/
[12] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278886/
[13] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771339/